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ABSTRACT
Background: Ingenol mebutate is a newly
approved topical field therapy for actinic
keratosis (AK). It has a dual mechanism of
action comprising of a rapid induction of
necrosis that specifically targets dysplastic
cells, as well as neutrophil-mediated
immunostimulatory effects. Such a dual
mechanism allows for this agent to clear AK
lesions in as little as two to three daily
applications, thus providing for improved
treatment outcomes and patient satisfaction.
Review: Given that this is a new dermatologic
therapy, this review summarizes the key
literature surrounding this agent. This review
covers the indications for use, mechanisms of
action, method of administration, efficacy and
safety profile and important drug interactions
of ingenol mebutate.
Conclusions: Ingenol mebutate should be
considered a highly relevant field therapy for
AK and the prevention of progression to
squamous cell carcinoma.
Keywords: Actinic keratosis; Dermatology;
Field therapy; Ingenol mebutate; Ingenol
3-angelate; Picato; Solar keratosis; Squamous
cell carcinoma
INTRODUCTION
Actinic keratosis (AK) is an area of dysplastic
epidermal keratinocytes that undergo
transformation due to substantial ultraviolet
(UV) exposure [1], and the distribution of
these lesions reflects areas of the body that
are most sun-exposed, namely the face, scalp
and arms. Within these regions, numerous
lesions are often found and premalignant
cells are thought to exist within the normal
skin alongside AK, so called ‘field
cancerization’ [2]. The rate of transformation
to squamous cell carcinoma (SCC) is low [3],
however, the overall risk of skin cancer is
increased in the presence of AK, therefore,
warranting their detection and treatment.
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Current treatment modalities available for AK
comprise lesion-directed therapies such as
cryotherapy and surgical excision, and the
field-directed therapies, namely the topical
agents 5-fluorouracil, diclofenac and
imiquimod [4]. The advantage of field
therapies is that they target both clinically
apparent and subclinical lesions over a
contiguous area of application [5]. Developed
in Australia, ingenol mebutate (Picato, LEO
Pharma A/S, Ballerup, Denmark) is a promising
new topical chemotherapeutic that is quickly
gaining acceptance as an effective field therapy
against AK [6]. Ingenol mebutate was approved
for use in Australia in 2013. It is derived from
the sap of the Euphorbia peplus plant, which
has already been in widespread use as a
traditional herbal remedy for various
dermatological lesions [7]: Ingenol mebutate
has been trialed for other skin lesions such as
superficial basal cell carcinoma [8]. A key
reason behind the increasing relevance of
ingenol mebutate as a treatment for AK is
that it is efficacious in the destruction of AK
lesions after a period of as little as 2–3 days [9],
compared with the current topical agents that
are applied for weeks to months [10]. This
shorter duration of application translates to a
number of obvious clinical benefits; a shorter
duration of adverse effects, should they occur,
as well as improved patient adherence
comparative to alternative treatments. Given
the relative infancy of ingenol mebutate as a
dermatologic therapy, this brief review aims to
summarize the key points of this agent.
METHODS
A Medline search was performed in June 2014,
utilizing the key words and search terms
‘‘Ingenol mebutate,’’ ‘‘Picato,’’ ‘‘Ingenol-3-
angelate,’’ ‘‘Actinic keratosis’’ and ‘‘Field
therapy.’’ Advanced search parameters
included limiting the search to retrieving
English language abstracts and publication
dates were limited from 2000 to present,
yielding 1,530 results. Articles were then only
selected from the following journals: Journal of
the American Academy of Dermatology, Journal
of the European Academy of Dermatology and
Venereology, Cutis, Dermatology and Therapy
(Heidelb), JAMA Dermatology, Australasian
Journal of Dermatology, Journal of Cutaneous
Medicine and Surgery, NEJM and The Journal of
Clinical and Aesthetic Dermatology. This search
returned 55 articles. After assessing titles and
abstracts, eight journal articles were chosen as
suitable to review for mechanism of action and
five were chosen to review for efficacy and
safety. A further two articles were chosen to
describe the important drug interactions. Other
articles for contextual background were




Unique among topical agents utilized for the
field therapy of AK, ingenol mebutate possesses
a dual mechanism of action that enhances its
efficacy [11], expediting the process such that
lesion destruction is observed after a period of
2–3 days [6]. Ingenol mebutate exerts its effects
by acting as an agonist for intracellular protein
kinase C (PKC) [12], which induces rapid
cellular necrosis and a neutrophil-mediated
form of antibody-dependent cellular
cytotoxicity (ADCC).
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Rapid Cellular Necrosis
Ingenol mebutate preferentially induces a rapid
necrosis of the dysplastic keratinocytes of AK
[13] through activation of the pro-apoptotic
intracellular PKC, with subsequent
mitochondrial swelling and rupture of the
plasma membrane [12]. Keratinocytes that
have undergone normal differentiation are
resistant to the PKC mediated pro-apoptotic
effects on the mitochondria for reasons that
have yet to be defined [14].
Neutrophil-Mediated ADCC
In addition to having pro-apoptotic effects on
dysplastic cells, ingenol mebutate also has
immunostimulatory effects [15] which
effectively ‘mop-up’ any dysplastic epidermal
cells that might survive the immediate necrotic
effects. Activated keratinocytes provide a milieu
of cytokines that promote an infiltration of
neutrophils into the area of application [16].
The neutrophils then activate reactive oxygen
species and other cytotoxic mechanisms to lyse
dysplastic cells [6]. This process is further
enhanced by the action of ingenol mebutate
functioning as an adjuvant [9], stimulating
antibody production that stimulates cytotoxic
T cells against dysplastic cells.
Efficacy and Safety
A number of clinical trials have indicated
ingenol mebutate is effective following a short
duration of application, is well tolerated, safe
and has minimal local effects [7, 10, 17, 18].
Siller et al. [17]
Siller and colleagues conducted a multicenter,
randomized, double-blind, vehicle-controlled
phase IIa trial of ingenol mebutate at
concentrations of 0.0025%, 0.01% and 0.05%.
Two doses were administered: one on day 1 and
the second on either day 2 or day 8, and the
response assessed at day 85. Patients that had
five or more AK of 3–15 mm diameter were
selected for the trial. A total of 58 patients and
285 lesions were assessed. Anatomically, the
lesions were located predominantly on the
upper limbs, scalp and face, in keeping with
the usual areas of predilection of AK, and were
distributed equitably across the treatment arms.
Clinical efficacy was assessed on a per lesion and
per patient basis, with complete clearance
defined as no clinical evidence of disease and
marked clearance being 50–90% lesion
reduction. The greatest level of clinical efficacy
was seen with the 0.05% concentration of
ingenol mebutate gel. On a per lesion basis,
71% were completely cleared, while 67% of
patients receiving the 0.05% dosage had clinical
clearance of 80% or more of their lesions. Local
skin responses (LSR) were seen in 47% of
patients receiving the 0.05% concentration,
and for the most part were assessed as mild/
moderate, however, a total of 14 were recorded
as severe. The most commonly seen effects were
erythema, flaking/scaling/dryness and
scabbing/crusting. Scarring and/or abnormal
lesion proliferation did not occur in any of the
subjects.
Anderson et al. [10]
A phase IIb study examined the efficacy and
safety outcomes of field therapy for non-facial
AK lesions using ingenol mebutate at
concentrations of 0.025% and 0.05%. Patients
were randomized into four study cohorts.
Treatment using 0.025% concentration was
applied once daily for three consecutive days.
Treatment with the 0.05% concentration was
given daily to two groups: three consecutive
days of treatment or day 1 vehicle treatment
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followed by 2 days of treatment. Vehicle
treatment was applied for 3 days to the control
group. The primary efficacy end point was the
partial clearance rate. This was defined as the
proportion of patients at the end of the study
with at least 75% reduction in AK lesions in the
area of field treatment, compared with those
that were identified at baseline. This criterion
was achieved for all three of the dosing
regimens: 56.0% of the group receiving
0.025% for 3 days, 61.8% of the group
receiving 0.05% for 2 days and 75.4% of the
group receiving 0.05% for 3 days. Compared
with the vehicle group, the results were
statistically significant and indicated a dose-
dependent response. Three secondary efficacy
endpoints were included: the complete
clearance rate (the number of patients at the
end of the study with no clinically evident AK
lesions in the field area), the baseline clearance
rate (the number of patients with 100%
reduction in the amount of AK lesions
detected at baseline) and the percentage
reduction of the number of AK lesions (the
number of lesions at baseline minus the number
at the end of the study divided by the number at
baseline). These measures were all significantly
higher in those patients who received any of the
three ingenol mebutate regimes compared to
those who received the vehicle treatment. The
study also included subjective assessments of
patient satisfaction with their treatment, all
measures of which came back positive for
ingenol mebutate compared with the vehicle
treatment. Safety end points included the
incidence and grade of LSRs, the incidence of
AEs, changes in laboratory tests between
screening and day 8, and the ‘global severity
rating’ (GSR)—the examiner’s overall clinical
impression of any local reactions observed
(mild, moderate or severe). LSRs peaked from
day 3 to 8, the most commonly observed
responses being erythema, flaking/scaling and
crusting. LSRs were scored on a scale from 0 to 4
and the individual scores were used to obtain a
composite LSR score (sum of the individual
scores at each examination in each treatment
cohort). The mean composite LSR scores were at
their highest at day 8 for the active treatment
groups, but had declined substantially by the
end of the study. The most common
application site AEs were pruritus, pain and
irritation, and were observed most frequently in
the 0.05% for 3 days cohort, further indicating a
dose-dependent response. All application site
reactions had resolved spontaneously by
4 weeks, and nil serious AEs were noted during
the follow-up period. No patients discontinued
participation in the trial due to an AE. The GSR,
as a function of observed LSRs, peaked at day 8
and dwindled towards the end of the study.
Lebwohl et al. [18]
This study looked at four double-blinded trials:
two trials considered lesions of the face and
scalp while the other two focused on lesions of
the trunk and extremities. Patients with facial
or scalp lesions were given either a placebo or
0.015% ingenol mebutate gel to apply for three
consecutive days while those with lesions
elsewhere on the trunk and extremities were
provided with either a vehicle treatment or
0.05% ingenol mebutate to be applied for
2 days. In both cases, patients were to self-
apply the gel to a 25 cm2 contiguous area once
daily. The facial lesion cohort was assessed for
safety at day 3 while the trunk and extremities
group was assessed on day 4, and both were
then assessed at days 8, 15, 29 and 57. In both
cohorts, efficacy was assessed at baseline and at
day 57. The primary end point assessment of
efficacy was complete clearance of all clinically
detectable AK lesions in the field area by the
end of the study. Complete clearance was
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observed in 42.2% of the face and scalp cohort
(compared to 3.7% with placebo) and 34.1% of
the trunk and extremities cohort (versus 4.7%
with placebo). The secondary endpoint was
partial clearance: a reduction of [75% of
clinically detectable AK lesions by the end of
the study. Partial clearance was achieved in
63.9% of the face and scalp group (compared
with 7.4% with placebo) and 49.1% among the
trunk and extremities group (versus 6.9% with
placebo). A further secondary end point was
the percentage difference in the amount of AK
lesions detected compared to the baseline. The
percentage change was zero among all patients
receiving placebo in all trials. A median
reduction of 83% of lesions was noted in the
face and scalp cohort and 75% in the trunk
and extremities cohort. Overall, the number
needed to treat value for ingenol mebutate to
achieve complete and partial clearance among
the face and scalp cohort was 2.6 and 1.8,
respectively, while for the trunk and
extremities cohort the number needed to
treat to achieve complete and partial
clearance was 3.4 and 2.4, respectively. Safety
end points that were considered were similar in
method to that of Anderson et al. [10]
described above: AEs, composite LSR scores,
scarring and pigmentation. However, the GSR
was not used in this study design. The most
common AEs reported across all four trials were
application site-specific pruritus, irritation and
pain, which is consistent with the findings of
Anderson et al. [10]. None of the four trials
highlighted any incidences of scarring or
changes in pigmentation. In the face and
scalp cohort, day 4 was the peak of the
composite LSR score, which then declined as
the study progressed. Individual LSR scores for
erythema were greater than 3 (on a scale of
0–4) in 69.7% of participants compared with
2.2% in the placebo group, and a small group
of the active treatment group had a score
greater than 3 for flaking or scaling, crusting,
swelling, vesiculation or ulceration. In the
trunk and extremities group, the composite
LSR had three peaks in a decrescendo pattern
at day 3, day 8 and day 15. Individual LSR
scores for erythema and flaking or scaling were
above 2 for the majority of subjects.
Vesiculation occurred in 43.6% of those on
active treatment and ulceration in 25.8%. The
patients who had complete clearance in the
two trials involving lesions of the face, as well
as those patients in one of the trials involving
body lesions, were monitored for a further
12 months.
Lebwohl et al. [7]
This is the follow-up study of the patients who
had achieved complete clearance in the above
study. These patients were seen at three
monthly intervals up to 12 months, during
which time further field therapy was not
administered, however, lesion-directed therapy
was available if the assessors deemed necessary.
Information was also recorded on possible
confounders such as concomitant treatments
and conditions that could alter immune
function. AK lesions in the field area were
counted at each three monthly visit: the
primary end point in this follow-up study was
recurrence of AK lesions in the field area.
Sustained clearance was defined as a field area
free of AK lesions after a 12-month period. For
the face and scalp cohort, the sustained
clearance rate was 46.1% and for the trunk
and extremities group was 44.0%. A second end
point was sustained lesion reduction, defined as
the total percentage reduction of AK lesions in
the field area at 12 months compared to the
baseline. For the face and scalp this was 87.2%
and for the trunk and extremities this was
86.8%.
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Based on the number of recurrences recorded
at each follow-up, the estimated median time
for new or recurrent lesions to occur in the field
area was calculated: 365 days for the face and
scalp and 274 days for the trunk and
extremities. AEs in the field area were also
assessed. Three patients suffered adverse
symptoms in the field area during the follow-
up period; however, the investigators did not
consider these to be related to the application of
ingenol mebutate. All three events resolved
completely. This absence of any AEs supports
the idea that ingenol mebutate has an excellent
safety profile.
Dosik et al. [19]
This study is an evaluation of the results of
three phase I trials in which ingenol mebutate
was applied to normal skin to determine its
sensitization potential, photo irritation
potential and photo allergic (photosensitizing)
potential, respectively. In the dermal
sensitization study, none of the subjects
experienced reactions that would indicate an
allergic response. In the photo irritation study,
very mild erythema was observed in the field
area following irradiation that was considered
statistically significant compared to non-
irradiated areas. However, the erythema was
clinically at a level so mild that it did not
reflect photo irritation. Moderate erythema was
observed in the irradiated field area when
assessing for photo allergic potential,
however, since mild erythema is an accepted
LSR for ingenol mebutate; this was not
considered to be an AE. Thus, these three
pharmacology trials provide further evidence
for the safety profile of ingenol mebutate:
ingenol mebutate does not appear to have
any potential for skin sensitization, photo
irritation or photoallergy.
Important Drug Interactions
Ingenol mebutate gel is available in two doses:
0.015% for the face and 0.05% for the rest of
the body [12], administered as a field therapy
to a contiguous area roughly 25 cm2 around
the lesion. It is applied once daily in both
instances, for 3 days duration when applied to
the face and 2 days when applied to the body
[6]. Ingenol mebutate has no known drug
interactions and its metabolites have no
effect on cytochrome P450 enzymes [13],
hence there are currently no
contraindications to the use of this agent.
Blood levels of the drug are undetectable
following topical administration, indicating
that systemic absorption does not occur [10].
Therefore, ingenol mebutate has not been
associated with any systemic AEs [20].
CONCLUSIONS
Ingenol mebutate is proving to be a promising
new addition to the available repertoire of field
therapies for the treatment of AK. Delivering
similar outcomes to the more established field
therapies available, in a matter of days,
improves patient convenience and, therefore,
improves compliance with treatment.
Furthermore, at the doses approved for
administration the safety profile of ingenol
mebutate appears excellent. Local effects are
mild and self-resolving within a short space of
time (owing to the short duration of
administration) while systemic effects appear
to be negligible. However, a number of caveats
should be considered. First, the therapeutic
limit is determined by the amount of product
available in the commercial dose. Ingenol
mebutate is packaged in doses with sufficient
product to cover a field area of 25 cm2, which
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translates to an area roughly the size of the
dorsum of the hand. This might be ample for
field therapy of facial lesions, however, over
more widespread anatomical locations, such as
the trunk, multiple doses could potentially be
required to cover the total expanse of field
cancerization. This would undoubtedly lead to
added cost to the patient requiring multiple
doses, which could detract from its improved
levels of compliance. More importantly,
insufficient product could open up the
potential for an inadequate spread of field
treatment over larger areas of skin. A second
limitation lies in an inherent risk with topical
therapies such as ingenol mebutate, in that they
theoretically only mediate an effect on the
superficial extent of a lesion, leaving the more
basal layers intact. Deeper SCC lesions could
ultimately result from this, requiring further
treatment, and this is an important
consideration.
On balance, this agent appears to have a
place alongside 5-fluorouracil, diclofenac and
imiquimod as suitable topical agents for the
field therapy of AK.
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